• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Editorial on "The AvaALL Randomized Clinical Trial".关于“AvaALL随机临床试验”的社论
J Thorac Dis. 2019 May;11(Suppl 9):S1237-S1240. doi: 10.21037/jtd.2019.02.62.
2
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.贝伐珠单抗联合标准治疗在晚期非小细胞肺癌患者疾病进展后的安全性和疗效：AvaALL 随机临床试验。
JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13.
3
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.评价贝伐珠单抗联合铂类化疗一线治疗后疾病进展的晚期非鳞状非小细胞肺癌患者继续使用贝伐珠单抗的随机 IIIb 期试验：AvaALL（MO22097）试验的治疗原理和方案动态。
Clin Lung Cancer. 2011 Nov;12(6):407-11. doi: 10.1016/j.cllc.2011.05.002. Epub 2011 Jun 25.
4
Randomized trial of epidural injections for spinal stenosis published in the New England Journal of Medicine: further confusion without clarification.《新英格兰医学杂志》发表的硬膜外注射治疗椎管狭窄症的随机试验：进一步的困惑，没有澄清。
Pain Physician. 2014 Jul-Aug;17(4):E475-88.
5
Early editorial manuscript screening versus obligate peer review: a randomized trial.早期编辑手稿筛选与强制同行评审：一项随机试验。
Ann Neurol. 2007 Apr;61(4):A10-2. doi: 10.1002/ana.21150.
6
Randomized clinical trials in Clinical Rehabilitation.《临床康复》中的随机临床试验。
Clin Rehabil. 2005 May;19(3):233-6. doi: 10.1191/0269215505cr871ed.
7
Uncertainty about the safety of supplemental glutamine: an editorial on "A randomized trial of glutamine and antioxidants in critically ill patients".补充谷氨酰胺的安全性不确定：对“危重症患者谷氨酰胺和抗氧化剂的随机试验”的社论。
Hepatobiliary Surg Nutr. 2015 Feb;4(1):76-9. doi: 10.3978/j.issn.2304-3881.2014.08.01.
8
Clinical trial registration in physical therapy journals: a cross-sectional study.物理治疗期刊中的临床试验注册：一项横断面研究。
Phys Ther. 2014 Jan;94(1):83-90. doi: 10.2522/ptj.20120531. Epub 2013 Sep 5.
9
A randomized trial of unruptured brain arteriovenous malformations trial: an editorial review.未破裂脑动静脉畸形试验的随机试验：一篇编辑评论
Stroke. 2014 Oct;45(10):3147-8. doi: 10.1161/STROKEAHA.114.004614. Epub 2014 Aug 19.
10
Editorial comment on Karlsson et al. "Cognitive behavior therapy in women with fibromyalgia. A randomized clinical trial".
Scand J Pain. 2015 Oct 1;9(1):68-69. doi: 10.1016/j.sjpain.2015.08.005.

引用本文的文献

1
Local Treatment of Non-small Cell Lung Cancer with a Spray-Dried Bevacizumab Formulation.喷雾干燥贝伐珠单抗制剂治疗非小细胞肺癌的局部治疗。
AAPS PharmSciTech. 2021 Aug 31;22(7):230. doi: 10.1208/s12249-021-02095-7.

本文引用的文献

1
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.贝伐珠单抗联合标准治疗在晚期非小细胞肺癌患者疾病进展后的安全性和疗效：AvaALL 随机临床试验。
JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13.
2
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
3
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.LKB1 表达与接受化疗和贝伐珠单抗治疗的晚期非小细胞肺癌患者的生存改善相关。
Clin Cancer Res. 2017 Jul 1;23(13):3316-3324. doi: 10.1158/1078-0432.CCR-16-2410. Epub 2017 Jan 24.
4
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.联合免疫治疗和抗血管生成治疗在晚期 NSCLC 协同治疗中的潜力。
J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8.
5
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.抗血管内皮生长因子癌症治疗的停药会通过肝脏再血管化机制促进转移。
Nat Commun. 2016 Sep 1;7:12680. doi: 10.1038/ncomms12680.
6
International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.意大利胸外科肿瘤学会抗血管生成药物治疗非小细胞肺癌国际专家小组会议：现实与希望。
J Thorac Oncol. 2016 Jul;11(7):1153-69. doi: 10.1016/j.jtho.2016.03.015. Epub 2016 Apr 5.
7
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.在晚期非鳞状非小细胞肺癌患者中，使用卡铂、培美曲塞和贝伐单抗进行诱导治疗后，培美曲塞和贝伐单抗维持治疗与培美曲塞单药维持治疗的比较。
Eur J Cancer. 2016 May;58:30-7. doi: 10.1016/j.ejca.2016.01.013. Epub 2016 Feb 27.
8
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.贝伐单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌后疾病进展时继续使用贝伐单抗（日本西部肿瘤学组5910L）：一项开放标签、随机、2期试验
Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1.
9
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.贝伐珠单抗治疗非鳞状非小细胞肺癌伴无症状、未经治疗的脑转移患者（BRAIN）：一项非随机、二期研究。
Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.
10
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.厄洛替尼单药或联合贝伐珠单抗作为 EGFR 突变的晚期非鳞状非小细胞肺癌患者的一线治疗（JO25567）：一项开放标签、随机、多中心、Ⅱ期研究。
Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27.

Editorial on "The AvaALL Randomized Clinical Trial".

作者信息

Bonanno Laura, Pavan Alberto, Pasello Giulia, Indraccolo Stefano

机构信息

Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.

Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padova, Italy.

出版信息

J Thorac Dis. 2019 May;11(Suppl 9):S1237-S1240. doi: 10.21037/jtd.2019.02.62.

DOI:10.21037/jtd.2019.02.62
PMID:31245096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6560574/
Abstract
摘要